المؤلفون: Tripathy D; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Im SA; Seoul National University Hospital, Cancer Research Institute, and Seoul National University College of Medicine, Seoul, South Korea., Colleoni M; Division of Medical Senology, Istituto Europeo di Oncologia, Milan, Italy., Franke F; Hospital de Caridade de Ijuí, Cacon, Ijuí, Brazil., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Harbeck N; Breast Center, Department of Obstetrics and Gynaecology, University of Munich, Munich, Germany., Hurvitz SA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Chow L; Organisation for Oncology and Translational Research, Hong Kong Special Administrative Region, China., Sohn J; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Lee KS; Research Institute and Hospital, National Cancer Center, Goyang, South Korea., Campos-Gomez S; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico., Villanueva Vazquez R; Institut Català d'Oncologia, Hospital Moisès Broggi, Barcelona, Spain., Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Babu KG; HCG Curie Centre of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, India., Wheatley-Price P; University of Ottawa, Ottawa, ON, Canada., De Laurentiis M; Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy., Im YH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Kuemmel S; Breast Unit, Kliniken Essen-Mitte, Essen, Germany., El-Saghir N; American University of Beirut Medical Center, Beirut, Lebanon., Liu MC; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Carlson G; Novartis, East Hanover, NJ, USA., Hughes G; Novartis, Basel, Switzerland., Diaz-Padilla I; Novartis, Basel, Switzerland., Germa C; Novartis, East Hanover, NJ, USA., Hirawat S; Novartis, East Hanover, NJ, USA., Lu YS; National Taiwan University Hospital, Taipei, Taiwan. Electronic address: yslu@ntu.edu.tw.

المصدر: The Lancet. Oncology [Lancet Oncol] 2018 Jul; Vol. 19 (7), pp. 904-915. Date of Electronic Publication: 2018 May 24.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*administration & dosage , Antineoplastic Agents, Hormonal/*administration & dosage , Breast Neoplasms/*drug therapy , Breast Neoplasms/*genetics , Purines/*administration & dosage, Administration, Oral ; Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Humans ; Internationality ; Kaplan-Meier Estimate ; Letrozole/administration & dosage ; Middle Aged ; Neoplasm Invasiveness/pathology ; Neoplasm Staging ; Premenopause/drug effects ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Tamoxifen/administration & dosage ; Treatment Outcome ; Young Adult

المؤلفون: Gianni L; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: gianni.luca@hsr.it., Pienkowski T; Postgraduate Medical Education Centre, Warsaw, Poland., Im YH; Samsung Medical Centre, Seoul, South Korea., Tseng LM; Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan., Liu MC; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan., Lluch A; Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain., Starosławska E; St John's Cancer Centre, Lublin, Poland., de la Haba-Rodriguez J; Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain., Im SA; Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Pedrini JL; Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil., Poirier B; Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada., Morandi P; Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy., Semiglazov V; N N Petrov Research Institute of Oncology, St Petersburg, Russia., Srimuninnimit V; Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand., Bianchi GV; Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Magazzù D; Fondazione Michelangelo, Milan, Italy., McNally V; Roche Products Limited, Welwyn, UK., Douthwaite H; Roche Products Limited, Welwyn, UK., Ross G; Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK., Valagussa P; Fondazione Michelangelo, Milan, Italy.

المصدر: The Lancet. Oncology [Lancet Oncol] 2016 Jun; Vol. 17 (6), pp. 791-800. Date of Electronic Publication: 2016 May 11.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoadjuvant Therapy*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Inflammatory Breast Neoplasms/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Receptor, ErbB-2/*metabolism, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Inflammatory Breast Neoplasms/pathology ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prognosis ; Survival Rate ; Time Factors ; Trastuzumab/administration & dosage ; Young Adult

المؤلفون: Gianni L; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. gianni.luca@hsr.it, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P

المصدر: The Lancet. Oncology [Lancet Oncol] 2012 Jan; Vol. 13 (1), pp. 25-32. Date of Electronic Publication: 2011 Dec 06.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Biomarkers, Tumor/*metabolism , Breast Neoplasms/*drug therapy , Inflammation/*pathology , Receptor, ErbB-2/*metabolism, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Asia ; Biomarkers, Tumor/antagonists & inhibitors ; Brazil ; Breast Neoplasms/enzymology ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Canada ; Chemotherapy, Adjuvant ; Docetaxel ; Europe ; Female ; Humans ; Mastectomy ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Protein Kinase Inhibitors/administration & dosage ; Receptor, ErbB-2/antagonists & inhibitors ; Taxoids/administration & dosage ; Time Factors ; Trastuzumab ; Treatment Outcome ; Young Adult